absenc
interferon
nebul
background
therapi
patient
plan
enrol
actual
patient
enrol
patient
moder
patient
per
china
nation
standard
patient
recruit
screen
elig
patient
enrol
treat
danoprevir
boost
ritonavir
presenc
absenc
interferon
nebul
background
therapi
day
discharg
hospit
treatment
patient
never
receiv
antivir
therapi
lopinavirritonavir
interferon
nebul
prior
treatment
danoprevir
boost
ritonavir
treatment
experienc
patient
receiv
least
one
dose
antivir
therapi
lopinavirritonavir
interferon
nebul
prior
treatment
danoprevir
boost
ritonavir
treatment
regimen
dose
frequenc
danoprevir
mg
per
tablet
tablet
time
twice
per
day
ritonavir
mg
per
tablet
tablet
time
twice
per
day
administ
aerosol
inhal
interferon
nebul
million
unit
time
twice
per
day
condit
patient
monitor
daili
attend
physician
routin
laboratori
test
blood
index
biochem
paramet
chest
comput
tomographi
ct
carri
need
accord
china
nation
standard
follow
four
condit
must
met
prior
discharg
normal
bodi
temperatur
day
significantli
recov
respiratori
symptom
lung
imag
show
obviou
absorpt
recoveri
acut
exud
lesion
two
consecut
rtpcr
neg
test
nucleotid
acid
respiratori
track
sampl
interv
least
one
day
furthermor
patient
review
expert
committe
compris
elit
clinician
discharg
patient
sign
inform
consent
form
ethic
committe
hospit
approv
studi
chines
adult
year
old
gender
pneumonia
patient
infect
confirm
posit
rtpcr
demonstr
respiratori
symptom
imagingconfirm
pneumonia
defin
china
nation
standard
patient
newli
diagnos
patient
never
receiv
antivir
treatment
danoprevirritonavir
treatment
initi
within
day
less
diagnosi
experienc
patient
might
receiv
antivir
therapi
dosag
treatment
durat
recommend
china
nation
standard
women
partner
plan
pregnanc
month
studi
will
take
effect
contracept
measur
within
day
first
administr
studi
drug
patient
agre
would
particip
clinic
trial
within
day
last
administr
studi
drug
patient
will
sign
inform
consent
form
sever
patient
met
one
follow
condit
respiratori
rate
rr
time
min
rest
state
arteri
partial
pressur
oxygen
concentr
oxygen
mmhg
kpa
critic
patient
met
one
follow
condit
respiratori
failur
need
mechan
ventil
shock
organ
failur
combin
icu
treatment
sever
liver
diseas
child
pugh
score
c
ast
time
upper
limit
patient
contraind
specifi
label
ritonavir
tablet
pregnanc
test
femal
subject
screen
period
posit
research
judg
patient
suitabl
particip
clinic
studi
exampl
patient
multipl
basic
diseas
etc
realtim
pcr
rtpcr
test
gene
perform
clinic
laboratori
ninth
hospit
nanchang
follow
test
kit
instruct
daan
gene
manufactur
guangzhou
china
lowest
detect
limit
kit
copiesml
briefli
nasal
phlegm
swab
specimen
collect
put
steril
tube
contain
ml
viral
transport
medium
total
cellular
rna
isol
trizol
reagent
invitrogen
transport
medium
rtpcr
conduct
lightcycl
roch
mix
pcr
solut
pcr
solut
b
sampl
rna
one
tube
posit
control
use
determin
posit
sampl
chest
ct
scan
conduct
use
highspe
dualslic
spiral
ct
ge
usa
ct
imag
axial
thinsect
noncontrast
undergon
mm
reconstruct
efficaci
endpoint
includ
time
discharg
rate
two
consecut
rtpcr
neg
test
nucleotid
acid
respiratori
track
sampl
sampl
interv
least
one
day
apart
lung
imag
show
obviou
absorpt
recoveri
acut
exud
lesion
significantli
improv
respiratori
symptom
normal
bodi
temperatur
least
day
total
moder
patient
enrol
includ
two
naiv
patient
nine
experienc
patient
baselin
demograph
characterist
enrol
patient
illustr
tabl
age
rang
patient
year
old
male
total
patient
two
experienc
patient
patient
patient
histori
hypertens
symptom
report
ill
onset
mainli
fever
cough
short
breath
two
naiv
patient
hospit
day
respect
experienc
patient
hospit
median
durat
day
key
paramet
patient
present
tabl
illustr
graphic
figur
gener
nine
patient
experienc
lopinavirritonavir
along
interferon
nebul
treatment
enrol
switch
danoprevirritonavir
treatment
includ
four
patient
interferon
nebul
five
patient
without
interferon
nebul
switch
two
naiv
patient
receiv
danoprevirritonavir
plu
interferon
nebul
treatment
initi
danoprevirritonavir
treatment
first
neg
rtpcr
test
occur
median
day
rang
day
obviou
absorpt
ct
scan
occur
median
day
rang
day
two
treatment
patient
receiv
danoprevirritonavir
plu
interferon
nebul
upon
hospit
medic
histori
treatment
variou
examin
one
two
patient
patient
describ
detail
februari
woman
close
contact
patient
test
posit
nasal
swab
rtpcr
thu
admit
hospit
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
vital
sign
patient
show
bodi
temperatur
bt
oxygen
satur
spo
ambient
air
breath
sound
normal
initi
underli
diseas
onset
morn
februari
given
first
dose
danoprevir
boost
ritonavir
along
interferon
nebul
februari
lower
lung
show
multipl
diffus
patchshap
area
groundglass
opac
ggo
especi
obviou
left
lower
lung
base
chest
ct
scan
figur
laboratori
result
reveal
lymphopenia
l
elev
platelet
l
tabl
februari
day
receiv
danoprevir
boost
ritonavir
treatment
patient
nt
show
abnorm
symptom
vital
sign
lower
lobe
bilater
lung
show
decreas
ggo
patchshap
area
compar
previou
imag
februari
indic
partial
absorpt
figur
rtpcr
result
nasal
swab
becam
neg
result
indic
patient
quick
respons
treatment
danoprevir
boost
ritonavir
along
interferon
nebul
februari
day
receiv
danoprevir
boost
ritonavir
treatment
ggo
patchshap
area
lung
significantli
decreas
densiti
scale
figur
compar
previou
imag
februari
rtpcr
result
nasal
swab
repeatedli
neg
februari
februari
patient
given
last
dose
danoprevir
boost
ritonavir
along
interferon
nebul
sinc
met
four
discharg
standard
describ
method
section
patient
discharg
hospit
day
nine
treatment
experienc
patient
lopinavirritonavir
plu
interferon
nebul
treatment
rang
day
four
patient
experienc
lopinavirritonavir
plu
interferon
nebul
treatment
day
ct
scan
worsen
switch
danoprevirritonavir
interferon
nebul
medic
histori
treatment
variou
examin
one
patient
patient
describ
detail
februari
man
admit
hospit
posit
rtpcr
nucleic
acid
test
nasal
swab
famili
member
diagnos
februari
base
chest
ct
scan
subpleur
area
right
lower
lung
show
ggo
figur
admiss
patient
report
histori
chest
distress
fatigu
show
sign
fever
short
breath
nausea
diarrhea
histori
hypertens
even
februari
given
first
dose
kaletra
lopinavir
mg
ritonavir
mg
per
tablet
tablet
time
twice
per
day
along
interferon
nebul
februari
patient
report
still
chest
distress
soft
thin
stool
still
report
occasion
cough
white
sputum
appear
patient
continu
lopinavirritonavir
treatment
receiv
rehydr
support
care
februari
day
receiv
lopinavirritonavir
treatment
lower
lung
show
consolid
along
ggo
patchshap
area
base
ct
scan
figur
therefor
even
februari
lopinavirritonavir
treatment
stop
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
patient
switch
danoprevir
boost
ritonavir
along
interferon
nebul
februari
patient
weak
posit
rtpcr
test
viral
rna
nasal
swab
februari
day
receiv
danoprevir
boost
ritonavir
treatment
right
lower
lung
show
shrunken
patchshap
area
decreas
densiti
ggo
figur
day
rtpcr
test
nasal
swab
becam
neg
remain
neg
next
day
rtpcr
test
morn
februari
patient
receiv
last
dose
danoprevir
boost
ritonavir
treatment
sinc
met
four
discharg
standard
describ
method
section
patient
discharg
hospit
day
five
patient
fail
lopinavirritonavir
plu
interferon
nebul
switch
danoprevirritonavir
without
interferon
nebul
medic
histori
treatment
variou
examin
one
patient
patient
describ
detail
februari
woman
perman
resid
wuhan
citi
admit
hospit
due
maximum
bt
rtpcr
posit
nasal
swab
occasion
cough
white
sputum
vital
sign
patient
show
bt
ambient
air
patient
halfyear
histori
hypertens
patient
given
first
dose
lopinavirritonavir
tablet
time
twice
per
day
along
interferon
nebul
even
februari
februari
base
ct
scan
subpleur
area
lower
lung
tonguelik
segment
left
lung
show
ggo
patchshap
area
figur
februari
februari
patient
show
slightli
fluctuat
bt
maximum
minimum
cough
white
sputum
anorexia
diarrhea
yellow
thin
stool
laboratori
result
reveal
leukopenia
l
lymphopenia
l
tabl
februari
day
receiv
lopinavirritonavir
treatment
ggo
patchshap
area
show
slightli
higher
densiti
figur
compar
previou
ct
imag
februari
februari
day
receiv
lopinavirritonavir
treatment
patient
report
improv
appetit
sleep
cough
white
sputum
remain
ct
scan
show
signific
chang
obat
serv
compar
previou
ct
imag
februari
opac
tonguelik
segment
increas
figur
februari
patient
receiv
last
dose
lopinavirritonavir
interferon
nebul
treatment
durat
lopinavirritonavir
interferon
nebul
exceed
recommend
china
nation
standard
result
lopinavirritonavir
interferon
nebul
stop
februari
switch
danoprevir
boost
ritonavir
without
interferon
nebul
februari
receiv
danoprevirritonavir
treatment
rtpcr
test
neg
nasal
phlegm
swab
februari
day
switch
danoprevir
boost
ritonavir
patient
show
improv
white
blood
cell
count
l
tabl
ct
scan
show
ggo
patchshap
area
decreas
densiti
compar
previou
ct
imag
februari
indic
absorpt
lung
figur
februari
patient
receiv
last
dose
danoprevir
boost
ritonavir
februari
ct
scan
show
lesion
tonguelik
segment
lung
indic
valu
lower
minimum
refer
valu
indic
valu
higher
maximum
refer
valu
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
